Brief: Codiak Reports Additional Positive Phase 1 Results For ExoIL-12

Codiak BioSciences,.

04/02/2021 12:48

Feb 4 (Reuters) - Codiak BioSciences, Inc.  CDAK.O :
    * CODIAK REPORTS ADDITIONAL POSITIVE PHASE 1 RESULTS FOR
EXOIL-12™
CONFIRMING LOCAL PHARMACOLOGY AND DOSE SELECTION FOR SAFETY AND
EFFICACY TRIAL IN EARLY-STAGE CUTANEOUS T CELL LYMPHOMA (CTCL)
PATIENTS
    * CODIAK BIOSCIENCES, INC. - PLAN TO INITIATE MULTI-DOSE
STUDY IN
CTCL PATIENTS, WITH DATA ANTICIPATED BY YEAR-END 2021
    * CODIAK BIOSCIENCES, INC. - PHARMACODYNAMIC RESULTS CONFIRM
LOCALIZED EXOIL-12 PHARMACOLOGIC ACTIVITY WITHOUT SYSTEMIC IL-12
EXPOSURE

Source text for Eikon:  ID:nGNX46JWyf 
Further company coverage:  CDAK.O 

 ((Reuters.Briefs@thomsonreuters.com;))